3 Jun 2013 11:24

Â
Â
Â
Â
Â
Hikma Pharmaceuticals PLC
Voting Rights and Capital
Â
LONDON, 3 June 2013, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 197,886,828 ordinary shares with voting rights. There are no shares held in treasury.
Â
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
Â
- ENDS -
Â
Enquiries
Â
Hikma Pharmaceuticals PLC | Â | |
Peter Speirs Company Secretary  | +44 20 7399 2760  | |
 |
Â
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.
Â